• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Tetrahydrouridine Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755621

Tetrahydrouridine is a competitive cytidine deaminase inhibitor and multidrug resistance modulator. It makes tumor cells more sensitive to radiation therapy making it useful for cancer treatment. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Tetrahydrouridine, Inhibitor
Full Product Name
Tetrahydrouridine
Product Synonym Names
THU; NSC-112907; NSC112907; NSC-112907; NSC 112907; NSC 112907
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
248.24
Solubility
DMSO: 100mg/mL (402.85mM)
H2O: 50mg/mL (201.43mM) Need ultrasonic
Water: Insoluble
DMSO: Soluble
(<1mg/ refers to the product slightly soluble or insoluble)
Formula
C9H16N2O6
SMILES
C1CN(C(=O)NC1O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
CAS Number
18771-50-1
Target & IC50
cytidine deaminase (CDA)

Product References and Citations for Tetrahydrouridine, inhibitor

Funamizu N, et al. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 2012;7(5):e37424.
Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB 3rd, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, Roussel MF. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors. J Neurooncol. 2015 Oct 30. [Epub ahead of print] PubMed PMID: 26518542.
Terse P, et al. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33(2):75-85.
Mano Y, Sakamaki K, Ueno T, Kita K, Ishii T, Hotta K, Kusano K. Validation of a hydrophilic interaction ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of gemcitabine in human plasma with tetrahydrouridine. Biomed Chromatogr. 2015 Sep;29(9):1343-9. doi: 10.1002/bmc.3429. Epub 2015 Feb 2. PubMed PMID: 25641274.
Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015 Mar;75(3):537-46. doi: 10.1007/s00280-014-2674-7. Epub 2015 Jan 8. PubMed PMID: 25567350; PubMed Central PMCID: PMC4344391.
Terse P, Engelke K, Chan K, Ling Y, Sharpnack D, Saunthararajah Y, Covey JM. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33(2):75-85. doi: 10.1177/1091581814524994. Epub 2014 Mar 17. PubMed PMID: 24639139; PubMed Central PMCID: PMC4001115.

Other Notes

Small volumes of Tetrahydrouridine, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Tetrahydrouridine purchase

MBS5755621 is an inhibitor targeting Tetrahydrouridine.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000